Consecutive Regulatory Approvals from Global Regulatory Agencies

Provepharm SAS, a French pharmaceutical company, has achieved consecutive regulatory approvals for its fluorescent diagnostic agent, Zyogreen (indocyanine green), in global markets. Zyogreen received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in April 2026 and was promptly launched in the local market on July 1. Subsequently, on July 9, it obtained New Drug Application (NDA 218579) approval from the U.S. Food and Drug Administration (FDA). This development significantly strengthens Provepharm's position in the existing diagnostic dye market and is expected to set a new standard in the field of precision surgical guidance, which has a high unmet need. With the sequential approval schedule now in place, the company is poised to enter a full-fledged commercialization phase.

Ready-to-Use Formulation: Transforming the Operating Room

The key highlight of this FDA approval is that Zyogreen has been recognized as a new formulation (Type 3 - New Dosage Form). Existing indocyanine green (ICG) diagnostic agents are typically supplied as lyophilized powders, requiring healthcare professionals to dissolve them in sterile water immediately before surgery, which can be cumbersome. In contrast, Zyogreen is developed as a ready-to-use liquid formulation, reducing preparation time in busy operating rooms and significantly minimizing the potential risk of microbial contamination during the preparation process. This improved convenience and safety are expected to rapidly increase its acceptance among healthcare professionals in clinical practice.

Applications in Precision Medicine and Fluorescence-Guided Surgery

Zyogreen, when injected into the body, binds to plasma proteins and emits strong fluorescence when exposed to near-infrared light. This allows for the visualization of sentinel lymph nodes, which are involved in the spread of cancer cells, during breast cancer surgery, enabling surgeons to minimize the extent of resection. It is also used as an essential diagnostic tool in various clinical settings, including ocular angiography in ophthalmology, hepatic function tests, and cardiac output measurements. With the increasing popularity of fluorescence-guided surgery, which aids in real-time visualization during surgery, the clinical value of this drug is expected to be further enhanced.

Market Competition and Provepharm's Positioning

The global indocyanine green (ICG) market is currently dominated by existing powder-based products, such as IC-Green from Novadaq Technologies. Provepharm already offers Bludigo (indigotindisulfonate sodium) and Provayblue (methylene blue) for urogynecological surgery, successfully diversifying its portfolio of surgical visualization agents. With its unique advantage of being a liquid formulation, it is expected to rapidly gain market share from existing products. The increasing demand for fluorescent diagnostic agents, driven by the widespread adoption of robotic surgery systems such as da Vinci, also creates a favorable market environment for Provepharm.

Commercialization Strategy and Challenges for Long-Term Growth

Provepharm plans to rapidly expand its distribution network from the UK to Europe and North America, starting with its commercial launch in the UK. In addition to its own marketing efforts, it is expected to pursue partnerships with major robotic surgery equipment manufacturers to encourage the bundled prescription of Zyogreen with the equipment. However, due to the liquid formulation, storage and distribution temperature control (cold chain) are more critical compared to existing powder formulations, and efficient supply chain management will be key to securing long-term profitability. Overall, this series of approvals is clearly a turning point for Provepharm to emerge as a leading player in the global diagnostic drug market.